S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
NASDAQ:SANA

Sana Biotechnology Stock Forecast, Price & News

$8.51
-0.50 (-5.55%)
(As of 01/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$8.34
$9.05
50-Day Range
$8.63
$21.87
52-Week Range
$7.95
$44.60
Volume
803,576 shs
Average Volume
988,105 shs
Market Capitalization
$1.61 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive SANA News and Ratings via Email

Sign-up to receive the latest news and ratings for Sana Biotechnology and its competitors with MarketBeat's FREE daily newsletter.


Sana Biotechnology logo

About Sana Biotechnology

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops in vivo and ex vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease; and SC187 for heart failures. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.

Headlines

Sana Biotechnology (NASDAQ:SANA) Reaches New 12-Month Low at $8.15
January 24, 2022 |  americanbankingnews.com
Sana Biotechnology (NASDAQ:SANA) Reaches New 52-Week Low at $10.64
January 18, 2022 |  americanbankingnews.com
Sana Biotechnology (NASDAQ:SANA) Stock Price Down 3.7%
January 12, 2022 |  americanbankingnews.com
Sana Biotechnology (NASDAQ:SANA) Reaches New 52-Week Low at $12.02
January 10, 2022 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SANA
Fax
N/A
Employees
265
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Net Income
$-285.30 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$1.61 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
11/07/2021
Today
1/25/2022
Next Earnings (Estimated)
3/23/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.40 out of 5 stars

Medical Sector

1131st out of 1,416 stocks

Biological Products, Except Diagnostic Industry

176th out of 206 stocks

Analyst Opinion: 3.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -












Sana Biotechnology (NASDAQ:SANA) Frequently Asked Questions

Is Sana Biotechnology a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sana Biotechnology in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Sana Biotechnology stock.
View analyst ratings for Sana Biotechnology
or view top-rated stocks.

Are investors shorting Sana Biotechnology?

Sana Biotechnology saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 9,790,000 shares, an increase of 23.6% from the December 15th total of 7,920,000 shares. Based on an average trading volume of 590,100 shares, the short-interest ratio is currently 16.6 days. Currently, 12.8% of the shares of the stock are sold short.
View Sana Biotechnology's Short Interest
.

When is Sana Biotechnology's next earnings date?

Sana Biotechnology is scheduled to release its next quarterly earnings announcement on Wednesday, March 23rd 2022.
View our earnings forecast for Sana Biotechnology
.

How were Sana Biotechnology's earnings last quarter?

Sana Biotechnology, Inc. (NASDAQ:SANA) issued its quarterly earnings data on Sunday, November, 7th. The company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.03.
View Sana Biotechnology's earnings history
.

What price target have analysts set for SANA?

4 analysts have issued 12 month price objectives for Sana Biotechnology's stock. Their forecasts range from $34.00 to $45.00. On average, they expect Sana Biotechnology's stock price to reach $38.50 in the next year. This suggests a possible upside of 352.4% from the stock's current price.
View analysts' price targets for Sana Biotechnology
or view top-rated stocks among Wall Street analysts.

Who are Sana Biotechnology's key executives?

Sana Biotechnology's management team includes the following people:
  • Dr. Steven D. Harr, Pres, CEO & Director (Age 51, Pay $829.25k)
  • Dr. Richard C. Mulligan, Exec. Vice Chairman & Head of SanaX (Age 66, Pay $954.45k)
  • Mr. Christian Hordo M.B.A., Sr. VP & Chief Bus. Officer (Age 38, Pay $485.03k) (LinkedIn Profile)
  • Mr. Nathan Hardy M.B.A., Sr. VP & CFO (Age 45)
  • Ms. Shanna Clouse Peek, Sr. VP & Head of Corp. Operations
  • Brittany Mccleery, Accounting Mang.
  • Dr. Edward Rebar Ph.D., Sr. VP & CTO (Age 53)
  • Mr. James J. MacDonald J.D., Exec. VP, Gen. Counsel & Sec. (Age 46)
  • Ms. Robin Andrulevich, Exec. VP & Chief People Officer (Age 55)
  • Dr. Sunil Agarwal, Exec. VP, Head of Devel. & Chief Medical Officer (Age 51)

When did Sana Biotechnology IPO?

(SANA) raised $322 million in an initial public offering (IPO) on Thursday, February 4th 2021. The company issued 15,000,000 shares at a price of $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and BofA Securities served as the underwriters for the IPO.

What is Sana Biotechnology's stock symbol?

Sana Biotechnology trades on the NASDAQ under the ticker symbol "SANA."

Who are Sana Biotechnology's major shareholders?

Sana Biotechnology's stock is owned by a number of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (5.96%).
View institutional ownership trends for Sana Biotechnology
.

Which major investors are buying Sana Biotechnology stock?

SANA stock was bought by a variety of institutional investors in the last quarter, including Baillie Gifford & Co..
View insider buying and selling activity for Sana Biotechnology
or or view top insider-buying stocks.

How do I buy shares of Sana Biotechnology?

Shares of SANA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sana Biotechnology's stock price today?

One share of SANA stock can currently be purchased for approximately $8.51.

How much money does Sana Biotechnology make?

Sana Biotechnology has a market capitalization of $1.61 billion. The company earns $-285.30 million in net income (profit) each year or ($9.29) on an earnings per share basis.

How many employees does Sana Biotechnology have?

Sana Biotechnology employs 265 workers across the globe.

What is Sana Biotechnology's official website?

The official website for Sana Biotechnology is sana.com.

Where are Sana Biotechnology's headquarters?

Sana Biotechnology is headquartered at 188 EAST BLAINE STREET SUIT 400, SEATTLE WA, 98102.

How can I contact Sana Biotechnology?

Sana Biotechnology's mailing address is 188 EAST BLAINE STREET SUIT 400, SEATTLE WA, 98102. The company can be reached via phone at 206-701-7914 or via email at [email protected].


This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.